Oncology/Hematology

Accumulating evidence of possible benefit warrants randomized trials, experts say

Long-term follow-up of low-risk pancreatic cystic lesions may be necessary

And randomized trial shows safety is on par

Long-term follow-up consistent with earlier report, a hint of benefit in high-grade disease

U.S. study supports findings from a global trial using an external control arm

New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment

Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG

POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance

Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety

News, features, and commentary about cancer-related issues

All-oral combination indicated for patients ineligible for intensive chemotherapy

A 21-year-old woman visited her doctor for multiple moles on her chest that first developed in her early teenage years and progressively increased in size and quantity over the years. Can you diagnose the patient?

"I feel wonderful, 100%," he said in an interview

More patients of all ages skip sentinel lymph node biopsy, get less aggressive RT or none at all

Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma

Resolution occurred after stopping dulaglutide, no obvious clues to mechanism

Oregon oncologist had a positive test, awaiting confirmation while remaining asymptomatic

Survival rate surpasses historical outcomes in a small phase I study

Lower mortality seen in observational study, but experts cast doubt on underlying data

Stage IV disease rates significantly increased in both men and women

Monthly prescription rates among patients with cancer more than doubled after talk of cures

EZH2 inhibitor tazemetostat (Tazverik) is being withdrawn from global markets

Looking only at regional differences may miss state-level needs

Deaths directly attributed to vitamin K deficiency bleeding have started to climb in recent years

News, features, and commentary about cancer-related issues

Rash, diarrhea, nausea, and other potential side effects to expect

Alongside improved colorectal cancer treatment, benefits are "more modest," expert says

Higher tumor grade, more residual tumor after neoadjuvant therapy were only significant factors

Also in TTHealthWatch: treating uncomplicated UTIs in women

Here's what two brain surgeries taught me about public health and care access

Requests for treatment with daraxonrasib must come from licensed U.S. physicians

Oral agent in second-line more than doubled median PFS in patients with ESR1 mutations

Agency staff expressed uncertainty over whether PFS benefit was "clinically meaningful"